Stocks Health care GNLX

NASDAQ · Health care

GENELUX Corp (GNLX)

It posted a net loss of $35.6M. In fiscal 2025 capital spending exceeded operating cash flow by $26.4M. At June 30, 2026 it held $9.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What GENELUX Corp does

GENELUX Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GNLX.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where GNLX ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What GENELUX Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026
2. June 22, 2026
   Shareholder vote results 8-K
3. May 7, 2026
   Quarterly report 10-Q · period to March 31, 2026
4. April 29, 2026
   Annual report to shareholders ARS
5. April 29, 2026
   Additional proxy material DEFA14A
6. April 29, 2026
   Proxy statement DEF 14A
7. March 19, 2026
   Securities offering prospectus 424B5
8. March 19, 2026
   Employee stock plan registration S-8
9. March 19, 2026
   Material agreement 8-K
10. March 19, 2026
    Annual report 10-K · period to December 31, 2025

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 2, 2026. Insider transactions on SEC

Insider trades

What the people running GENELUX Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $146.7K worth of shares in the last 90 days and bought none on the open market.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about GNLX

What does GENELUX Corp do?

GENELUX Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GNLX.

Is GENELUX Corp profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $35.6M.

When did GENELUX Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.

Similar companies

Compare GNLX with

Compare GNLX with any company

Follow GNLX

Get an email when GENELUX Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow GNLX: get an email when it files

Where the numbers come from

Financial figures are the values GENELUX Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.